Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$49.74 USD
+0.25 (0.51%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $49.74 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BMY 49.74 +0.25(0.51%)
Will BMY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
Alexandria Sells Asset to Redeploy in Development, Redevelopment Moves
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Other News for BMY
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
Bristol Myers reports data from Phase 3 DAYBREAK trial
Bristol Myers Squibb Zeposia shows long-term efficacy